Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Obstet Gynaecol Res ; 48(11): 2935-2945, 2022 Nov.
Article in English | MEDLINE | ID: mdl-35908182

ABSTRACT

AIM: To develop a treatment and management algorithm for vulvar abscess. METHODS: We evaluated the clinical findings and treatment modalities of patients hospitalized with vulvar abscess via a comprehensive literature review and a clinical study. Patients with a diagnosis of vulvar abscess (n = 28) between 2015 and 2019 in the gynecology clinic of our hospital were included in the clinical study. Each patient's age, obstetric history, body mass index, presence of concomitant diseases, abscess culture and size, mean length of hospital stay, treatment modalities, and recurrence rate were recorded. RESULTS: The mean age and body mass index of the patients were 47.7 ± 11.5 years and 30.3 ± 2.7 kg/m2 , respectively. Diabetes mellitus was the most common concomitant disease (60.7%, n = 17). The abscesses of 22 (78.5%) patients drained spontaneously. The abscess cavities of the remaining six (21.4%) patients were treated via incisional drainage. Gentamicin + clindamycin or levofloxacin + metronidazole were used as the primary antibiotic treatment. Hemovac drains were placed in four (14.2%) patients with abscess sites greater than 5 cm. By applying our treatment methods, 26 (92.8%) of our patients were discharged with full recovery, and two patients (7.2%) were referred due to uncontrolled diabetes mellitus. The recurrence rate of vulvar abscess was 0%. CONCLUSIONS: This is the first study in the literature to present a successful algorithm for the treatment and management of vulvar abscess. Our treatment methods shed light on the treatment and management of vulvar abscess.


Subject(s)
Abscess , Vulvovaginitis , Female , Humans , Abscess/drug therapy , Tertiary Care Centers , Retrospective Studies , Drainage , Anti-Bacterial Agents/therapeutic use , Algorithms
2.
Clin Anat ; 35(6): 732-737, 2022 Sep.
Article in English | MEDLINE | ID: mdl-35416338

ABSTRACT

This study aims to compare the uterine body longitudinal axis, uterine body transverse axis, uterine cervix longitudinal axis and anterior cervical axis angle measured ultrasonographically between women with pelvic inflammatory disease (PID) and healthy controls. Women aged 18-45 years with PID and healthy controls were included in the study. Demographic characteristics, uterine body long axis, uterine body transverse axis, uterine cervix long axis and anterior cervical axis angle of PID patients and healthy controls were evaluated. Gravida, parity, history of smoking were significantly higher in the PID group (n = 75) than the control group (n = 74). The uterine body longitudinal axis (p = 0.001) and transverse axis (p = 0.005) were significantly lower, and the cervix longitudinal axis (p < 0.001) and the anterior uterocervical angle (p < 0.001) were significantly higher in the PID group than the control group. Binary logistic regression analysis showed that uterine body (UTX) longitudinal axis (p = 0.005), uterine cervix longitudinal axis (p < 0.001) and UCA (p < 0.001) were significant predictors of PID. Uterine body longitudinal axis, uterine cervix longitudinal axis, and UCA can be associated to PID.


Subject(s)
Pelvic Inflammatory Disease , Uterine Cervical Neoplasms , Cervix Uteri/diagnostic imaging , Female , Humans , Pregnancy , Uterus
3.
Saudi Med J ; 33(12): 1270-7, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23232673

ABSTRACT

Current published data makes clear the relationship between genital human papillomavirus (HPV) infection and cervical cancer. Although there is an opportunity for screening programs that could obviate the disease, cervical cancer still remains the second most common cancer among women worldwide. The subtypes HPV 16 and 18 affect the anogenital tract mucosal surfaces, and accounts for nearly 70% of all cervical cancers, and 90% or more of anal cancer cases. When the 493,000 new cases of cervical cancer and 274,000 deaths per year are taken into consideration, the importance of treatment and prophylaxis modalities for HPV can clearly be recognized. With the molecular and epidemiological studies that have focused on the oncogenicity and immunobiological structure of HPV, the main strategy is to develop prophylactic and therapeutic vaccines. Here, recent data concerning HPV infections and vaccination is discussed.


Subject(s)
Alphapapillomavirus/immunology , Papillomavirus Vaccines/administration & dosage , Uterine Cervical Neoplasms/prevention & control , Animals , Female , Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 , Humans , Pregnancy
SELECTION OF CITATIONS
SEARCH DETAIL
...